eptinezumab


( Last Updated : May 11, 2022)
Generic Name:
eptinezumab
Project Status:
Pending
Therapeutic Area:
Migraine
Manufacturer:
Lundbeck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Vyepti
Project Line:
Reimbursement Review
Project Number:
SR0743-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the prevention of migraine in adults who have at least four migraine days per month and have experienced an inadequate response, intolerance, or contraindication to at least two oral prophylactic migraine medications.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the prevention of migraine in adults who have at least 4 migraine days per month.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.